A method for performing apheresis of mammals, including humans, is set forth which does not require separation of the blood into plasma or any other portion. Termed whole blood apheresis herein, this advance makes it possible to perform apheresis more quickly and efficiently with less stress for the patient. This application also discloses important advances in apheresis for therapeutic treatments, including treatments for sepsis and AKI using whole blood apheresis, and immunotherapy where targets that interfere with recovery are removed by apheresis and gene-engineered fragments previously removed are reintroduced. Use of selective withdrawal through apheresis expands possible resolutions of illnesses and conditions previously thought to be untreatable.

A fluid filtration system comprising a cross-flow filter is arranged to permit a first pump to recirculate part of the retentate of the filter to the inlet of the cross-flow filter and a second pump to return part of the permeate to the inlet of the cross-flow filter. A third pump is configured supply source fluid to the inlet of the filter. The flow path between the second pump and the cross-flow filter inlet may include an adsorption filter that may selectively remove contaminants, toxins, or pathogens in the permeate. A controller may control the first, second and third pumps to provide predetermined flow ratios among the fluid flow paths of the system in order to achieve a desired filtration level. This system may be applicable to the removal of harmful substances from blood, by first separating the plasma from the blood and then removing harmful substances from the plasma.

The devices and methods of the present invention can be used to capture and remove COVID-19 mediating nanoparticles and/or exosomes associated with COVID-19 or similar disease from the circulatory system of patients in need thereof, including those with post-COVID-19 syndrome or similar post-disease sequelae so-called “long haul” symptoms of COVID-19 or similar disease. The present invention benefits patients by providing lectin based extracorporeal methods for binding and physically removing SA RS-C7oV-2 virions, or fragments thereof, from the circulatory system. Also provided are lectin based extracorporeal methods of binding and physically removing non-viral COVID-19 mediating nanoparticles. Also disclosed herein are devices and methods for reducing the levels of biomarkers and markers of morbidity/mortality of diseases such as COVID-19 and similar diseases, including cytokines, such as IL-6, Troponin T, and D-dimer.

A dialysis fluid system includes a dialysis fluid inlet; a dialysis fluid outlet; a pump positioned and arranged to pump dialysis fluid through the dialysis fluid inlet and the dialysis fluid outlet; and an inductive heater located between the dialysis fluid inlet and the dialysis fluid outlet, the inductive heater including a fluid flowpath positioned and arranged to receive non-heated dialysis fluid from the dialysis fluid inlet and to output heated dialysis fluid to the a dialysis fluid outlet, a conductive heater element located within the fluid flowpath so as to be or act as a secondary coil of a transformer, and a primary coil of the transformer located outside of the fluid flowpath and positioned so as to magnetically induce a current into the conductive heater element, causing the conductive heater element and surrounding fluid to heat.

Process and system for acellular therapy in a human subject are provided. The process and system relate to an acellular therapy using therapeutic extracellular vehicles fused to biological material obtained from the subject, via transfusion by extracorporeal systems. The process for acellular therapy is in a subject in need of such therapy.

A method is provided for removing red blood cells from a suspension comprising red blood cells, white blood cells, platelets and plasma using a spinning membrane separator. The method comprises: a) flowing whole blood into the gap of the spinning membrane separator; b) collecting red blood cells and white blood cells in the gap and passing plasma and platelets through the membrane; c) introducing a first quantity of lysing buffer into the gap; d) incubating the red blood cells, white blood cells and lysing buffer in the gap for a period of time to cause a lysis reaction with the red blood cells; e) introducing a second quantity of lysing buffer into the gap to displace the first quantity of lysing buffer and a first quantity of red blood cell debris out of the gap; f) introducing a first quantity of wash buffer into the gap to quench the lysis reaction and displace the second quantity of lysing buffer and a second quantity of red blood cell debris out of the gap; and g) introducing a second quantity of wash buffer into the gap to flow washed white blood cells out of the housing.

A portable and wearable renal therapy system is provided. The system comprises: a purification device configured to remove toxins from process fluid and deliver a therapeutic substance to the process fluid; and a drug delivery device coupled to the purification device. The drug delivery device comprises: a reservoir for a fluid comprising a therapeutic substance; and a fluid connection coupling the drug delivery device with the purification device, the fluid connection configured for fluidly communicating the reservoir with the process fluid.

An embodiment provides a method for treating a body fluid of a patient with an inflammatory cytokine storm, including: removing the body fluid from a patient; applying a treatment to the body fluid, wherein the treatment comprises an antibody that joins with an antigen in the body fluid to form an antibody -antigen complex; removing the antibody-antigen complex from the body fluid; and returning the body fluid to the patient. Other aspects are described and claimed.

An embodiment provides a method for treating a body fluid, including: removing the body fluid from a patient; applying a treatment to the body fluid, wherein the treatment comprises an antibody that joins with an antigen in the body fluid to form an antibody-antigen complex; removing the antibody-antigen complex from the body fluid; and returning the body fluid to the patient. Other aspects are described and claimed.

The present disclosure provides apparatuses and systems for delivering a measureable absorbed-dose of a gaseous activating agent to a fluid including a biological liquid and/or cells. The apparatuses or systems include a gas-fluid contact device configured to controllably rotate or oscillate a control member having an interior surface in contact with the fluid and a control system configured to control rotation or oscillation of the contact member by the gas-fluid contact device. In some embodiments, the control system is further configured to control absorption of the gaseous activating agent by the fluid. The present disclosure also provides methods of treating a fluid including a biological liquid or cells with a gaseous activating agent to controllably activate the fluid.